New study on Apligraf in diabetic foot ulcer healing is published- Novartis

A new comparative effectiveness analysis, published online in Wound Repair & Regeneration, reported that Apligraf, from Novartis, has demonstrated improved outcomes over Epifix by a wide margin. The large-scale analysis, the first of its kind, examined healing rates of patients with diabetic foot ulcers (DFUs) who were treated either with Organogenesis' Apligraf or with Epifix, made by MiMedx Group, Inc.

Researchers found that DFUs treated with Apligraf had significantly higher rates of healing in significantly less time compared to those treated with Epifix, increasing the probability of healing by 97%. When compared to Epifix, Apligraf improved frequency of wound closure at 12 weeks (48% vs. 28%), and at 24 weeks (72% vs. 47%), and healed wounds faster (median weeks: 13.3 vs. 26.0). These results indicate cost savings with Apligraf based on application frequency and faster time to healing.